Probiomics becomes Bioxyne
“Our firm focus is to create shareholder value by commercialising our promising new therapy aimed at the major global medical market for chronic obstructive pulmonary disease (COPD) which includes emphysema and bronchitis. The name change comes at a time when our focus is moving away from research and development to actively seeking to commercialise our first therapeutic asset currently known as HI-164OV,” he said.
Mr Radford confirmed Bioxyne was on track for the planned mid-year release of data from a 320 patient clinical trial of HI-164OV.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.